IQVIA (IQV) Stock Forecast & Price Target

$196.92 +2.54 (+1.31%)

(As of 01:45 PM ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
4

Buy
15

Based on 19 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$256.50
30.26% Upside

According to the 19 analysts' twelve-month price targets for IQVIA, the average price target is $256.50. The highest price target for IQV is $300.00, while the lowest price target for IQV is $223.00. The average price target represents a forecasted upside of 30.26% from the current price of $196.92.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

IQV Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$256.50	$267.87	$265.67	$236.57
Forecasted Upside	30.26% Upside	17.33% Upside	6.72% Upside	12.91% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Bill Gates’s Next Big AI Bet: Stargate (Ad)

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	31.96% Upside	26,931.47% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent IQV News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Leerink Partners 1 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$260.00 ➝ $248.00	+28.58%
11/5/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$279.00 ➝ $240.00	+14.35%
11/4/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$286.00 ➝ $265.00	+26.24%
11/4/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$280.00 ➝ $265.00	+26.70%
11/1/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$290.00 ➝ $260.00	+24.32%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$260.00 ➝ $255.00	+22.30%
Top "Sleeping Giant" Crypto In The Market Now (Ad) Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late
11/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $265.00	+27.09%
11/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$270.00 ➝ $255.00	+22.30%
11/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Dodge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $270.00	+29.60%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$280.00 ➝ $250.00	+20.00%
11/1/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$256.00 ➝ $223.00	+8.35%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$276.00	+20.32%
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $265.00	+17.33%
7/31/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
7/23/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$295.00 ➝ $300.00	+24.28%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$190.00 ➝ $225.00	+4.52%
10/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$250.00 ➝ $229.00	+14.76%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$260.00	+17.71%
8/2/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $281.00	+28.44%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$235.00 ➝ $220.00	+16.88%
2/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$265.00	+14.17%
12/6/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$251.00	+18.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:04 PM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA Holdings Inc. has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
Analysts have been upgrading their price targets for IQVIA Holdings Inc., suggesting positive sentiment and potential for stock price appreciation.
IQVIA Holdings Inc. reported earnings per share (EPS) that exceeded analysts' estimates, demonstrating strong profitability.
The company's stock price has been trending upwards, showing positive momentum in the market.
IQVIA Holdings Inc. has a diverse range of services in advanced analytics, technology solutions, and clinical research, providing stability and growth potential in the life sciences industry.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

The stock's current price may be considered high based on its historical valuation metrics, potentially limiting short-term upside.
There could be regulatory risks associated with the healthcare and life sciences industry that may impact IQVIA Holdings Inc.'s operations and profitability.
Competition in the industry from other research and analytics companies could pose a challenge to IQVIA Holdings Inc.'s market share and growth prospects.
Market volatility and economic uncertainties may affect the demand for IQVIA Holdings Inc.'s services, leading to fluctuations in revenue and stock performance.
IQVIA Holdings Inc.'s debt-to-equity ratio of 1.80 may raise concerns about the company's leverage and financial stability in changing market conditions.

IQV Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $256.50, with a high forecast of $300.00 and a low forecast of $223.00.
: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.
: According to analysts, IQVIA's stock has a predicted upside of 30.26% based on their 12-month stock forecasts.
: IQVIA has been rated by research analysts at Barclays, BTIG Research, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, and Truist Financial in the past 90 days.
: Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.84 while the average consensus rating score for "medical" companies is 2.80. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

This page (NYSE:IQV) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target